MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

dMMR colon cancer

Search medical newsFind research, conditions and clinical updates
  • Home
  • dMMR colon cancer
Neoadjuvant Immunotherapy in dMMR Colon Cancer: A Breakthrough in Survival Outcomes
Posted inClinical Updates Gastroenterology Oncology

Neoadjuvant Immunotherapy in dMMR Colon Cancer: A Breakthrough in Survival Outcomes

Posted by By MedXY 11/09/2026
The NICHE-2 trial demonstrates that neoadjuvant immunotherapy with ipilimumab and nivolumab yields 100% three-year disease-free and five-year overall survival in mismatch repair-deficient colon cancer patients, marking a potential new standard of care.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Cost-Effectiveness of Visual Scanning Training for Post-Stroke Hemianopia: Insights from the SEARCH Trial and Related Evidence
  • Childhood Famine and Its Impact on Late-Life Tooth Loss: Unraveling the Role of Age Confounding
  • Neoadjuvant Immunotherapy in dMMR Colon Cancer: A Breakthrough in Survival Outcomes
  • Dupilumab in Pediatric Eosinophilic Esophagitis: Efficacy, Safety, and Translational Insights from Recent Clinical Evidence
  • Exploring HFE Genotype-Linked Arthropathy Beyond Genetic Haemochromatosis: Clinical and Pathophysiological Insights
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top